Bernard J. Vittone
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bernard J. Vittone.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 1985
Thomas W. Uhde; Jean-Philippe Boulenger; Peter Roy-Byrne; Marilla Geraci; Bernard J. Vittone; Robert M. Post
The longitudinal course of panic disorder and its associated symptoms were investigated in thirty-eight patients. The temporal relationships among panic attacks, generalized anxiety, agoraphobia and depression are described. Similar and different biological alterations in the tricyclic-responsive disorders of primary depression and panic disorder are reviewed and discussed.
Psychiatry Research-neuroimaging | 1984
Thomas W. Uhde; Peter P. Roy-Byrne; J. Christian Gillin; Wallace B. Mendelson; Jean-Philippe Boulenger; Bernard J. Vittone; Robert M. Post
Electroencephalographic sleep recordings were compared in patients with panic disorder and normal controls. Correlation coefficients of standard sleep parameters versus ratings of anxiety, depression, and panic attack frequency were calculated in the panic-anxious patients. Overall findings are discussed in the context of previous sleep studies in patients with depressive, anxiety, and obsessive-compulsive disorders.
Psychopathology | 1984
Thomas W. Uhde; Jean-Philippe Boulenger; Robert M. Post; Larry J. Siever; Bernard J. Vittone; David C. Jimerson; Peter Roy-Byrne
The experiences of human fear and anxiety are discussed within the context of locus ceruleus function in animals. The rationale for studying correlates of noradrenergic function, such as 3-methoxy-4-hydroxyphenethylene glycol (MHPG), is reviewed, and data demonstrating a positive correlation between plasma free MHPG and state anxiety in normal volunteers is presented. The behavioral effects of oral caffeine (240-720 mg), intravenous clonidine (2 micrograms/kg), and oral yohimbine (20 mg) were studied in various psychiatric patients and normal volunteers. Caffeine and yohimbine had anxiogenic properties; conversely, clonidine reduced self-rated measures of anxiety across a wide spectrum of psychiatric conditions. These findings expand previous research indicating that noradrenergic hyperactivity may be associated with many types of human fear and anxiety.
Journal of Affective Disorders | 1994
Thomas W. Uhde; Manuel E. Tancer; Cheryl Shea Gelernter; Bernard J. Vittone
In primates, social stress is associated with activation of the hypothalamic-pituitary-adrenal (HPA) axis. Social phobia is a common, often disabling, form of pathological anxiety characterized by marked distress in situations involving possible scrutiny or evaluation. Little is known about HPA function in patients with social phobia. We examined 24-hour excretion of urinary free cortisol (UFC) in 54 patients with social phobia and post-dexamethasone cortisol levels in 64 patients with social phobia and found no evidence of HPA-axis overactivity compared to normal controls, despite pathological levels of anxiety.
Australian and New Zealand Journal of Psychiatry | 1985
Bernard J. Vittone; Thomas W. Uhde
The authors present a review of existing literature along with new data regarding the phenomenology, differential diagnosis, course and treatment of panic disorder and agoraphobia. Panic attacks are viewed as central to the development of these disorders, and individual cognitive frameworks contribute to the manner in which a patients symptoms evolve. An apparent though unclear relation to depressive states is described. Substance abuse may also be a consequence of recurrent panic attacks. A scheme towards differential diagnosis of panic disorder from other psychiatric and medical disorders is proposed. Personality characteristics of these patients vary considerably, but certain factors, such as dependency, are common. Family relations are often strained and assume importance in treatment. Data on the longitudinal course of illness is presented implying a relationship of panic disorder to both depression and stressful life events in many patients. Treatments that thus far seem most effective are pharmacological and behavioural approaches. Imipramine, MAO inhibitors, and alprazolam currently appear to be the most useful medications employed, although other agents may at times be useful alternatives. Dietary interventions, family therapy, and group and individual psychotherapy are also reviewed and discussed as adjunctive therapies in the treatment of panic disorder.
Archives of General Psychiatry | 1991
Cheryl Shea Gelernter; Thomas W. Uhde; Peter Cimbolic; Diane B. Arnkoff; Bernard J. Vittone; Manuel E. Tancer; John J. Bartko
Biological Psychiatry | 1986
Thomas W. Uhde; Bernard J. Vittone; Larry J. Siever; Walter H. Kaye; Robert M. Post
Archives of General Psychiatry | 1989
Thomas W. Uhde; Murray B. Stein; Bernard J. Vittone; Larry J. Siever; Jean-Philippe Boulenger; Ehud Klein; Thomas A. Mellman
Neuropsychopharmacology | 1992
Thomas W. Uhde; Manuel E. Tancer; David R. Rubinow; Diana B. Roscow; Jean Philippe Boulenger; Bernard J. Vittone; George Gurguis; Marilla Geraci; Bruce Black; Robert M. Post
Psychopathology | 1984
Thomas W. Uhde; Jean-Philippe Boulenger; Robert M. Post; Larry J. Siever; Bernard J. Vittone; David C. Jimerson; Peter Roy-Byrne; L.A. Riblet; A.S. Eison; Michael S. Eison; D.P. Taylor; D.L. Temple; C.P. van der Maelen; Natraj Sitaram; S. Dube; D. Jones; Robert Pohl; S. Gershon; M. Lader; M. Rainey; Eva Ettedgui; B. Pohl; R. Balon; P. Weinberg; S. Yelonek; R. Berchou; Phil Skolnick; J.N. Crawley; J.R. Glowa; Steven M. Paul